Az immunfunkció értékelése a szepszisben
Sepsis leads to sustained immune system dysfunction resulting in increased susceptibility to secondary infection while in the hospital or after discharge. Consequently, many of the ~2 million Americans that develop sepsis every year will end up back in the ICU, weeks and months later. The objective of this study is to define the cellular and molecular mechanisms driving the dysfunction and reprogramming of T cells and B cells that mediate cellular and humoral immunity using a combination of phenotypic, functional, genomic, and metabolomic assays.
A tanulmány áttekintése
Tanulmány típusa
Beiratkozás (Becsült)
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Mrunmayi Tilak
- Telefonszám: 612-624-9990
- E-mail: mtilak@umn.edu
Tanulmányi helyek
-
-
Minnesota
-
Minneapolis, Minnesota, Egyesült Államok, 55455
- Toborzás
- University of Minnesota
-
Kapcsolatba lépni:
- Kristine Kancans
- E-mail: kanca008@umn.edu
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Mintavételi módszer
Tanulmányi populáció
Patients with and without sepsis in the ICU, compared to healthy volunteers
Leírás
ICU With Sepsis Inclusion Criteria:
-
Age ≥ 18
-
Presumed diagnosis of sepsis, defined as "patients with life-threatening organ dysfunction caused by a dysregulated host response to infection"
-
Patients in the ICU who meet 2 or more of the quick SOFA (qSOFA) definition along with organ dysfunction:
- Respiration rate ≥ 22 breaths/min and/or mechanically ventilated
- An alteration in mental status
- Systolic blood pressure of less than 100 mm Hg and/or receiving inotropes to maintain blood pressure AND/OR
- An acute change in SOFA score ≥2 points, consequent to the infection (can assume SOFA score = 0 in patients with no pre-existing organ dysfunction)
ICU Without Sepsis Inclusion Criteria:
- Age ≥ 18
- Patients requiring care at a M Health Fairview ICU due to high acuity of illness and no other evidence of sepsis
Healthy Volunteer Inclusion Criteria
- Age greater or equal to 18
- ASA status 1, 2 or 3
- May include patients who are receiving dialysis in an outpatient setting
Exclusion Criteria (all groups):
- Active cancer with chemotherapy and/or radiation treatment within the past 6 weeks
- Medication usage that includes immunosuppressive drugs, biologic agents, cytokines, growth factor and interleukins
- Steroid medication usage of > 300mg hydrocortisone per day (equivalent of > 20mg prednisone). Patients with chronic steroid use will be excluded, however patients who have had stress dose steroids administered following admission will be included.
- Patients with a history of, or who currently have evidence of autoimmune disease, including but not limited to: myasthenia gravis, Guillain Barré syndrome, systemic lupus erythematosus, multiple sclerosis, scleroderma, ulcerative colitis, Crohn's disease, autoimmune hepatitis, Wegener's granulomatosis, HIV/AIDS, etc.
- Patients with active or a history of acute or chronic lymphocytic leukemia
- Known history of chronic hepatitis B (HBV) infection and not on treatment with HBV nucleoside analogues prior to the current hospitalization, or HBV DNA > 100 IU/mL
- Known history of infection with hepatitis C (HCV) and currently undergoing treatment for HCV infection or has detectable HCV RNA
- Participation in another investigational interventional drug study within the past 4 weeks
- Current pregnancy
- Current incarceration
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Megfigyelési modellek: CASE_CONTROL
- Időperspektívák: PROSPECTIVE
Kohorszok és beavatkozások
Csoport / Kohorsz |
Beavatkozás / kezelés |
|---|---|
|
Egészséges önkéntesek
|
No intervention is included in this study |
|
ICU szepszisben szenvedő betegek
|
No intervention is included in this study |
|
ICU betegek szepszis nélkül
|
No intervention is included in this study |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
EliSpot - Day 1
Időkeret: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
EliSpot - Day 4
Időkeret: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
EliSpot - Day 7
Időkeret: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
EliSpot - Day 14
Időkeret: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
EliSpot - Day 21
Időkeret: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
EliSpot - Day 28
Időkeret: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Ex Vivo TNF Production - Day 1
Időkeret: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Ex Vivo TNF Production - Day 4
Időkeret: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Ex Vivo TNF Production - Day 7
Időkeret: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Ex Vivo TNF Production - Day 14
Időkeret: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Ex Vivo TNF Production - Day 21
Időkeret: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Ex Vivo TNF Production - Day 28
Időkeret: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 1
Időkeret: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 4
Időkeret: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 7
Időkeret: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 14
Időkeret: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 21
Időkeret: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 28
Időkeret: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Quantification of Cytokines in Serum - Day 1
Időkeret: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Quantification of Cytokines in Serum - Day 4
Időkeret: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Quantification of Cytokines in Serum - Day 7
Időkeret: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Quantification of Cytokines in Serum - Day 14
Időkeret: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Quantification of Cytokines in Serum - Day 21
Időkeret: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Quantification of Cytokines in Serum - Day 28
Időkeret: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Quantification of Chemokines in Serum - Day 1
Időkeret: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Quantification of Chemokines in Serum - Day 4
Időkeret: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Quantification of Chemokines in Serum - Day 7
Időkeret: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Quantification of Chemokines in Serum - Day 14
Időkeret: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Quantification of Chemokines in Serum - Day 21
Időkeret: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Quantification of Chemokines in Serum - Day 28
Időkeret: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Transcriptional Profiling - Day 1
Időkeret: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Transcriptional Profiling - Day 4
Időkeret: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Transcriptional Profiling - Day 7
Időkeret: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Transcriptional Profiling - Day 14
Időkeret: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Transcriptional Profiling - Day 21
Időkeret: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Transcriptional Profiling - Day 28
Időkeret: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
CBC - Day 1
Időkeret: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
CBC - Day 4
Időkeret: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
CBC - Day 7
Időkeret: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
CBC - Day 14
Időkeret: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
CBC - Day 21
Időkeret: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
CBC - Day 28
Időkeret: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Kutatásvezető: Thomas Griffith, PhD, University of Minnesota
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- URO-2025-34202
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .